CAR-T cell therapy research

Assessment of Q-PCR based vector copy numbers and viral titration in CAR T cell products, Probe vs SYBR Green.

The paper compares SYBR Green and Probe-based Q-PCR methods for measuring vector copy numbers and viral titration in CAR T cell products, finding Probe has lower contamination dependency.

Cell surface proteomics of patient-derived malignant rhabdoid tumor organoids identifies ROBO1 as potential CAR T cell target for pediatric solid tumors.

Refactored intracellular domains enhance CAR expression and function

This paper uses AI agents to design and refine CAR intracellular domains, resulting in a compact ICD that improves CAR expression and function.

Membrane-mediated cooperativity of antigen receptors and CD2 adhesion receptors in CAR-T cell activation

This study develops a model explaining how nanometre-scale changes in receptor dimensions affect CAR-T cell antigen sensitivity by linking physical principles to experimental observations.

Therapeutic Targeting of the TGFβ Pathway Augments CAR T cell Efficacy in Glioblastoma

This study shows that targeting the TGFβ pathway improves CAR T cell efficacy in glioblastoma by enhancing antitumor activity and modulating the tumor microenvironment.

Temporal mapping of the anti-tumor effects of nanobody-based MSLN.CAR-T cell therapy in metastatic solid tumors

This study tracks the temporal changes in the tumor microenvironment after nanobody-based CAR-T therapy, revealing dynamic gene expression shifts and identifying potential therapeutic targets.

Engineered T cells controlled by granulocyte colony-stimulating factor eradicate murine melanoma without lymphodepletion or interleukin-2

This study engineers T cells to respond to G-CSF instead of IL-2, enabling effective melanoma treatment without lymphodepletion or IL-2.

Lymphoma response to chimeric antigen receptor T cell therapy is driven by endogenous tumor-reactive CD8⁺ T cells

This study shows that durable CAR-T therapy in lymphoma requires cooperation with endogenous CD8 T cells, and tumors lacking MHC class I or CD58 resist treatment.

Pharmacologically regulated bioorthogonal stabilization domain for regulation of CAR T cells

This paper develops a pharmacologically controlled system for regulating CAR T cell function using estrogen receptor-based degron domains and FDA-approved compounds.

Reprogramming CAR-T cell function through synthetic cytokine receptors suppresses metastatic progression of TNBC

This study enhances CAR-T cell migration through synthetic cytokine receptors, reducing metastasis in TNBC mouse models.

Development and design rules for a modular human peptide-tag adaptor CAR T cell system

This study develops a modular CAR T cell system, BRiDGE CAR, and identifies design rules for its activity based on CAR and adaptor configurations.

Harnessing the PRDM1-PGC1A axis to enhance CAR T cell efficacy

This study identifies the PRDM1-PGC1A axis as a key regulator of CAR T cell function, showing that inhibiting PRDM1 or activating PGC1A improves CAR T cell efficacy in multiple tumor models.

A CAR T cell-amplified suppressive B cell circuit in AML

The paper identifies suppressive atypical memory B cells in AML that are amplified by CAR T cell interactions and shows that targeting both B cells and AML blasts can overcome this suppression.

Automated CAR-T Cell Manufacturing: from Research to Point of Care production.

This paper describes LimCORE, an automated system for CAR-T cell manufacturing that achieves comparable performance to existing methods while reducing operator time.

Stealth CAR-Tregs evade CD3 antibody therapy and skew immune responses toward regulation

This study shows that TRAC-/-CAR-Tregs survive CD3 antibody therapy better than TRAC+/+CAR-Tregs, shifting immune responses toward regulation.

PiggyBac transposon and transposase delivered in trans, in cis, and as mRNA for engineering CAR-T cells: a multi-objective optimization

This study compares three piggyBac transposon delivery methods for CAR-T cell engineering, finding that the ONE method offers highest efficiency but lower viability, while MRNA reduces transgene copy numbers at lower efficiency.

Low CAR affinity enhances T-cell synapse dynamics and activation

This study shows that low CAR affinity improves T-cell synapse dynamics and activation by promoting receptor turnover and signaling.

Fast receptor-antigen dissociation kinetics promote CAR-T cell tumor infiltration, functional fitness, and antitumor efficacy in solid tumors

Validation and analysis of 12,000 AI-driven CAR-T designs in the Bits to Binders competition

The paper validates and analyzes 12,000 AI-designed CAR-T binders from a global competition, identifying successful designs and factors improving their performance.

A signaling-optimized TIGIT chimeric switch receptor promotes metabolic fitness and antitumor efficacy of TCR/CAR T cells

This paper introduces a fine-tuned chimeric switch receptor (CSR) that enhances TCR/CAR T cell metabolic fitness and antitumor efficacy by optimizing signaling from the TIGIT domain.

Tumor cell-intrinsic stress states drive sensitivity to CAR T cell-therapy in pancreatic cancer

This study identifies tumor-intrinsic stress states as modulators of CAR T cell therapy response in pancreatic cancer using CRISPR screens and single-cell genomics.

A Lenalidomide-Inducible Suicide Switch for Gene- and Cell-Based Therapy

This paper introduces a lenalidomide-inducible suicide switch for gene- and cell-based therapies that enables safe and effective cell depletion without detectable leakiness.

Abrogating TGFβ signaling in TCR-engineered T cells and enhancing antigen processing by tumor cells promotes sustained therapeutic activity in pancreatic ductal adenocarcinoma

This study shows that blocking TGFβ signaling in TCR-engineered T cells and enhancing antigen processing in tumor cells improves their therapeutic effectiveness against pancreatic ductal adenocarcinoma.

HLA-A*11:01-Restricted T Cell Receptors Targeting Mutant NPM1 for Adoptive Cell Therapy in Acute Myeloid Leukemia

This study identifies two TCRs targeting mutant NPM1 in AML for adoptive therapy, showing specific anti-leukemic activity without cross-reactivity.

Obesity Impairs the Antitumor Activity of CAR-T Cells in Triple-Negative Breast Cancer

This study shows obesity impairs B7-H3.CAR-T cell antitumor activity and memory formation in TNBC by altering cytokine profiles and metabolic function.

Engineering CAR-T cells to remodel the mucin-rich cancer cell glycocalyx

This study engineers CAR-T cells to secrete KLK5, a protease that remodels the mucin-rich glycocalyx, enhancing CAR-T cell function and tumor control in xenograft models.

A Rationally Designed Transgene Drives CAR T Functional Persistence and Durable Regression of Solid Tumors

This paper designs a transgene that enhances CAR T cell persistence and tumor regression by integrating multiple engineered technologies in solid tumor models.

Low-dose radiopharmaceutical therapy enhances the efficacy of B7-H3 CAR T cells in murine metastatic neuroblastoma

This study shows that low-dose radiopharmaceutical therapy enhances the effectiveness of B7-H3 CAR T cells in treating metastatic neuroblastoma in mice.

Dual-targeted nanoparticles enable the ex vivo generation of cytotoxic and phagocytic CAR effector cells

This study develops dual-targeted lipid nanoparticles to enhance the ex vivo generation of CAR-T cells and CAR-monocytes, showing improved cytotoxic and phagocytic activity.

A Dynamically Regulated Designed IL-2 for Tumor-localized Signaling

This paper designs a dynamically regulated IL-2 variant that enhances tumor-specific immune responses while reducing systemic toxicity.